Clear cell renal cell carcinoma (CCRCC) evolves due to mutations in the Von Hippel-Lindau (VHL) tumor suppressor gene. Although the loss of VHL enables survival and proliferation of CCRCC cells, it is also expected to introduce vulnerabilities that may be exploited for therapeutics discovery. To this end, we developed a highthroughput screen to identify small molecules derived from plants, microorganisms, and marine organisms to which CCRCC cells are sensitive. Screening over 8,000 compounds using this approach, we report here the identification of the microbially derived compound carminomycin I (CA) as an effective inhibitor of VHLdefective (VHL À / À ) CCRCC cell proliferation. CA also induced apoptosis in CCRCC cells by a mechanism independent of p53 or hypoxia-inducible factor 2. We found that P-glycoprotein (P-gp) sequestered CA within the Golgi complex. Interestingly, Golgi sequestration was critical for the antiproliferative effects of CA and P-gp inhibitors abrogated this activity. Furthermore, CA induced cleavage of the Golgi protein p115 and the translocation of its C-terminal fragment to the nucleus. Finally, examination of the activity of the VHLinteracting Golgi protein, endoplasmic reticulum-Golgi intermediate compartment, showed that VHL could mediate protection from CA in CCRCC cells. Our natural product-based screening approach has revealed the P-gp-mediated localization of anticancer compounds within the Golgi in CCRCC cells as a potential strategy of targeting VHL-deficient CCRCC cells. Cancer Res; 71(1); 134-42. Ó2011 AACR.
Introduction
Clear cell renal cell carcinoma (CCRCC) is the most commonly found form of kidney cancer. It occurs in hereditary and sporadic forms both of which arise due to structural alterations in the von Hippel-Lindau (VHL) gene (1, 2) . The most studied function of the VHL gene product (pVHL) is the regulation of levels of the hypoxia-inducible factor (HIF)-a family of transcription factors (3) . However, the increasing number of proteins with which it interacts as well as genotype-phenotype correlations in VHL disease all strongly suggest that pVHL possesses functions unrelated to HIF that may contribute to the genesis and progression of CCRCC. How HIF-independent functions contribute to tumor development after pVHL inactivation, however, remains unclear. Elucidation of these functions should lead to enhanced understanding of renal carcinogenesis and should enable the identification of novel targets that may be exploited in therapeutic discovery.
Natural products (i.e., plant, microbial, and marine organismderived compounds) have in the past proved a fertile source of bioactive compounds that have led to both the development of newer chemotherapeutic interventions and a better understanding of the underlying disease biology. In the area of anticancer compounds, natural products either represent actual drugs (such as Taxol, vincristine, and camptothecin) or have served as the basis for the development of a large number of currently clinically approved drugs. We, therefore, set out to address the challenges of identifying small molecules selectively targeting VHL À / À CCRCC cells using a forward chemical genetics approach employing natural product-based high-throughput screening (HTS).
Materials and Methods

Cells and cell culture
The 786-O cell line was obtained from the repository of the Developmental Therapeutics Program at the National Cancer Institute. The cell lines UOK-121 and UOK-127 were obtained from the National Cancer Institute Urologic Oncology Branch Renal Cell Carcinoma Cell Line Repository. The cell lines have been characterized at the repositories using, among others, single nucleotide polymorphism arrays and by oligonucleotide-base HLA typing. They have also been subjected to spectral karyotyping and have been characterized for variations in short tandem repeats (4, 5) . All cell lines were placed under cryostorage after they were acquired from the repositories and used within 6 months of thawing fresh vials. Routinely, cells were grown in DMEM supplemented with 10% fetal bovine serum and incubated at 37 C in 5% CO 2 . Stably transduced 786-OVHL, UOK-121VHL, and UOK-127VHL as well 786-O, UOK-121, and UOK-127 cell lines were generated using retroviral gene delivery with or without VHL as described previously (6) . During this time, cell morphology, growth curve, and possible mycoplasma contamination were regularly checked to ensure the absence of contamination.
High-throughput screening
During the screening campaign, 5,000 cells of both 786-O and 786-OVHL cell lines were plated per well in different 384-well plates and the plates were incubated overnight. After this period, test compounds were added at a final concentration of 10 mmol/L. Reduction of 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide (XTT) by metabolically active cells to a colored product was used to assess the effect of compounds on cells after 24 hours. A total of 8,326 compounds were tested using this screening assay.
Analysis of cell death
Cells were treated with serial dilutions of either the vehicle control or hit compounds in a dose-response format and were incubated for 24 hours. Cell viability was assessed using the above XTT assay. Caspase activity in treated cells was determined using Caspase-Glo 3/7, 8, and 9 assays according to the manufacturer's instructions in 384-well plates (Promega). Lactate dehydrogenase release from necrotic cells into the extracellular fluid was determined using the CytoTox-ONE membrane integrity assay kit following the manufacturer's protocol (Promega).
Western blotting
After compound treatment, cells were trypsinized, neutralized, and pelleted. Cell pellets were washed twice with ice-cold PBS. Pellets were then lysed with NP-40 lysis buffer (Sigma) containing protease inhibitor cocktail (Roche), 1 tablet per 5 mL of lysis buffer and 1.02 mmol/L phenylmethylsulfonyl fluoride. Total protein concentration was determined using a BCA kit (Pierce) with bovine serum albumin (Sigma) as the standard. Cellular protein (10-50 mg) was resolved by SDS-PAGE and electrophoretically transferred onto polyvinylidene difluoride membranes (Invitrogen). The membranes were blocked with Odyssey blocking buffer (Li-Cor) overnight at 4 C and then incubated with specific primary antibodies. All antibodies except the following were obtained from Santa Cruz Biotechnology and used at 1:200 to 1:1,000 dilutions: VHL, PARP [poly (ADP-ribose) polymerase], cleaved PARP (Cell Signaling); a1-antitrypsin (A1AT), Bak (Abcam); and a-tubulin and b-actin (Sigma). GAPDH (glyceraldehyde 3-phosphate dehydrogenase), b-actin, or a-tubulin was used as a loading control and changes in protein levels shown were found to be significant relative to loading controls. Following incubation with primary antibody, membranes were washed and incubated with antimouse IRDye 680 and antirabbit IRDye 800 secondary antibodies (Li-Cor). Blots were scanned using an Odyssey infrared imaging system and processed using its software (Li-Cor). Band intensities were determined using the Odyssey band quantitation software after background subtraction using the median top-bottom method. Intensities of bands of interest were normalized to the signals from the corresponding loading control bands.
Cell-cycle analysis
Following treatment with 0.1 mmol/L of carminomycin I (CA) for 16 hours, 0.5 to 1.0 Â 10 6 /mL live 786-O and 786-OVHL cells were harvested and stained with propidium iodide using Krishan's buffer (0.1% sodium citrate, 0.02 mg/mL RNase A, 0.3% NP-40 and 50 mg/mL propidium iodide) at a pH of 7.4.
RNA interference and quantitative reverse transcription-PCR
HIF-2a targeted siRNA and control siRNA-termed mock were kind gifts from Dr. Olga Aprelikova of the Laboratory of Tumor and Stem Cell Biology at the National Cancer Institute and have been described previously. The sequence for the HIF-2 siRNA used was 5 0 -GGUGUGCUGUUUGGAGUUCdTdT-3 0 . A control siRNA-termed mock (target sequence 5 0 -GCGCGCTTTGTAGGATTCG-3 0 ) was purchased from Qiagen and had no significant homology to any known human sequence. The 786-O cells (1-2 Â 10 5 /well) were transfected with siRNA oligos (30-60 nmol/L final concentration) in 6-well plates, using Lipofectamine (Invitrogen) following the manufacturer's protocol. Forty-eight hours later, the transfected RCC cells were washed and used for subsequent experiments. Transduction of 786-O cells via lentiviral P-glycoprotein (P-gp) shRNA was carried out using commercially available lentiviral supernatants (Santa Cruz) following the manufacturer's protocol. Total RNA was extracted and purified using the RNeasy Mini Kit (Qiagen), and 2 mg total RNA was reverse transcribed using ImProm-II reverse transcription reagent (Promega). Primers and probes for human P-gp, HIF-2a, A1AT, and b-actin were purchased from Applied Biosystems (Assayson-demand).
P-gp ATPase assay
The assay was performed using the Pgp-Glo Assay kit (Promega) following the manufacturer's protocol.
a1-Antitrypsin ELISA
Cells were grown in T25-flasks to 80% confluence, and conditioned cell culture medium was harvested after 24 hours. For ELISA, 100 mL of undiluted conditioned medium was used. ELISA was conducted according to manufacturer's instructions (Alpco).
Immunocytochemistry
Cells grown on cover slips or seeded on glass chips with an O-or L-shaped fibronectin micropattern (Cytoo) were fixed with 4% fresh paraformaldehyde and permeabilized with either 0.1% Triton X-100 in PBS or cold methanol. Samples were blocked using Odessey blocking buffer overnight at 4 C. Anti-p115 targeting the p115 C-terminus (1:100, Novus Biologicals), anti endoplasmic reticulum-Golgi intermediate compartment (ERGIC)-53 (1:1,000, Alexis), anti-P-gp (1:100, Santa Cruz or 1:100 Abcam), and anti-GM130 (1:100, Epitomics) monoclonal antibodies were incubated with samples overnight at 4 C. Finally, the samples were washed and incubated for 45 minutes with the appropriate secondary antibody from among the following: Alexa Fluor 488 goat antirabbit; Alexa Fluor 488 chicken antigoat, and/or Alexa Fluor 594 goat antimouse (Invitrogen). Counterstaining was performed where shown using ProLong Gold antifade reagent with DAPI (Invitrogen) as the mounting medium. In some double-labeled experiments, 786-O cells were first transduced with Organelle Lights Golgi-RFP (Invitrogen) as a marker for the Golgi. Images were acquired using Zeiss LSM 510 microscopes at 63Â magnifications (Zeiss).
Image analysis
Images were processed with the program ImageJ (http:// www.uhnres.utoronto.ca/facilities/wcif/imagej/). Quantitative analysis of colocalization was performed using the plugin "colocalization threshold" of ImageJ. Details of the image analysis protocol can be found in the Supplementary Data.
Results
High-throughput screen
To identify small molecule inhibitors of VHL Fig. S1A ). Similarly, other VHL þ / þ cell lines were also generated using the VHL À / À CCRCC cell lines UOK-121 and UOK-127. Consistency and reproducibility of the HTS assay were assessed using a set of 352 compounds as a validation library. A very high correlation coefficient (0.954; R 2 ¼ 0.89À0.91) was obtained from 3 independent experiments. In addition, how well the assay performed during the screen was also routinely evaluated via determination of the Z-factor (7). The Z-factor determined during the screen for all plates with 786-O cells using actinomycin D at 10 mmol/L as the positive control and 1% DMSO as the negative control was found to be 0.68 AE 0.082 indicating that the assay performed well during HTS. In the primary screen, 56 compounds inhibited cell proliferation by more than 2-fold in 786-O cells compared with that in 786-OVHL cells with these compounds also showing at least 50% inhibition in 786-O cells.
Hit compounds identified in the primary screen were serially diluted and subjected to retesting in a doseresponse format. Of the 56 compounds identified as hits in the primary screen, 15 were found to show attenuation of cell proliferation in 786-O cells in a dose-dependent manner. To enable a broader evaluation of effect of hit compounds on VHL À / À cell proliferation, hits were also evaluated in paired VHL þ / þ and VHL À / À UOK-121 and UOK-127 cells.
All 15 hit compounds tested also showed differential inhibition of cell proliferation in paired UOK-121 and UOK-121VHL cells as well as in UOK-127 and UOK-127VHL cells (Fig. 1) . Because of its fluorescent nature, we chose one of the hit compounds, CA, as a model to illustrate the utility of natural products in providing a novel perspective on targeting cancer cells in general and CCRCC cells in particular.
Below, we present our findings from the follow-up work done using CA.
CA induces apoptosis in 786-O cells
The most studied function of pVHL is the negative regulation of HIF via ubiquitin-mediated degradation. Therefore, we examined whether the observed cytotoxicity in 786-O cells was HIF mediated and whether the observed resistance to CA in 786-OVHL cells was dependent on HIF downregulation. We found, however, that CA exerts its effects on 786-O cells through HIF independent mechanisms ( Supplementary  Fig. S2 ). The absence of lactate dehydrogenase release into the growth medium and the lack of vesicles that stained positive for beclin-1, Atg12, or LC3B also allowed the determination that CA did not curtail the viability of 786-O cells through either necrosis or autophagy. Measurement of caspase activity over a 24-hour period after CA treatment, on the other hand, revealed increased caspase-3 activity as early as 2 hours after treatment. More pronounced differential caspase-3 activity between 786-O and 786-OVHL cells became apparent after 24 hours at all CA concentrations tested 0.1 to 100 mmol/L (Supplementary Fig. S3A ). Significant differential caspase-8, and to a lesser extent caspase-9, activity in 786-O and 786-OVHL cells was observable only 24 hours after treatment at concentrations between 0.1 and 10 mmol/L ( Supplementary  Fig. 3 ). This suggested that apoptosis mediated by caspase-3 activation may contribute to the observed effect of CA on cell proliferation. Caspase-3 activation at lower CA test concentrations also appears not to directly correlate with activation of either caspase-8 or -9 suggesting that an alternative initiation pathway may play a role.
Real-time monitoring of effects of CA treatment on 786-O cells led to the observation of blebbing and changes to the cell membrane characteristic of apoptosis ( Supplementary  Fig. S3B ). Genomic DNA extracted from CA-treated 786-O cells also exhibited characteristic internucleosomal laddering of genomic DNA fragments in agarose gel electrophoresis ( Supplementary Fig. S3C ). Induction of apoptosis by CA in 786-O cells was further supported through monitoring PARP and caspase-3 cleavage as well as through changes in the levels of a panel of proteins commonly involved in apoptotic signaling via Western blotting ( Fig. 2A) . Finally, treatment of 786-O cells with the pan caspase inhibitors Z-VAD-fmk or Boc-D-fmk resulted in reversal of effects of CA on cell proliferation (Fig. 2B) . Taken together, these results indicate that CA curtailed proliferation of 786-O cells through induction of apoptosis.
CA induces survivin and p53 downregulation in 786-O cells
Resistance to cytokine-induced apoptosis in the 786-O cell line has been attributed to expression of high levels of apoptosis-inhibiting molecules (8) . We thus examined the effect of CA on the levels of expression of the inhibitor of apoptosis protein survivin. Western blotting of lysates from CA-treated cells revealed a decrease in survivin levels in 786-O cells, whereas its levels in 786-OVHL cells increased suggesting that CA owes its apoptotic effects in 786-O cells, in part, to its effects on survivin (Fig. 3) . The activation of caspase-2 has been reported to repress the transcription of the survivin (9) . Western blotting also revealed that CA treatment enhanced capsase-2 cleavage (Fig. 3A) . Next, because upregulation of survivin in malignant cells has also been associated with accelerated S-phase shift, resistance to G 1 arrest, and activation of Cdk2/cyclin E complex leading to Rb-phosphorylation (10), we looked at effects of CA on the cell cycle and cell-cycle checkpoint signaling pathway proteins. First, the distribution of live 786-O cells in each phase of the cell cycle was determined using flow cytometry following incubation with CA. The number of 786-O cells in S-phase significantly increased consistent with S-phase arrest (Fig. 3C) . We also found that CA treatment in 786-O cells was accompanied by a decrease in the levels of phosphorylated Rb and an increase in levels of cyclins D3 and E with no significant change in Cdk2 levels (Supplementary Fig. S4 ). Interestingly, cyclin D3 is known to induce the activation of caspase-2 (11) suggesting that caspase-2 mediated proapoptotic mitochondrial effects and downregulation of survivin both play a role in mediating the effects of CA on proliferation of 786-O cells.
To better understand the molecular mechanisms that result in the differential activity seen between 786-O and 786-OVHL cells in response to CA treatment, we also examined the role of factors commonly involved in regulating apoptotic response. Activation of p53 has been shown to induce apoptosis in 786-O cells treated with either indomethacin (12) or UV-radiation (13) . As a result, we first examined changes in p53 levels as well as changes in the levels of p53 downstream targets in both 786-O and 786-OVHL cells following CA treatment. Western blotting of 786-O protein lysates from treated cells showed that p53 levels in fact decreased in response to CA in 786-O cells (Fig. 3A) . In contrast, p53 levels in 786-OVHL cells increased in response to CA. We also looked at changes in the level of p53 targets such as p21 and p27. Both p21 and p27 levels decreased in response to treatment with CA in 786-O cells, suggesting that apoptosis may not be mediated through activation of the p53 pathway in 786-O cells.
Sensitivity to CA in 786-O cells is mediated through its active localization within the Golgi
Resistance to anthracycline compounds like CA is known to be mediated by the ATP-binding cassette transporter superfamily of membrane proteins. More pertinently, sequestration of the CA-related anthracycline daunorubicin within intracellular organelles has been reported to be mediated by P-gp (14). We, therefore, first looked at whether CA potentially was a substrate for P-gp. The results showed that CA stimulated basal P-gp ATPase activity by more than 4-fold suggesting that it is a substrate for transport by P-gp like other anthracycline antibiotics (Fig. 4A) . Because P-gp-mediated resistance to the anthracycline doxorubicin in OVCAR-3 cells is reversible by Cells were treated with serial dilutions of CA for 24 hours and data shown is expressed as percentage of XTT reduction relative to DMSO-treated cells. Each point represents mean AE SEM from 2 independent experiments with a point in an experiment averaged from 8 replicates.
other P-gp substrates, we looked at whether this resistance could also be reversed by CA. Pretreatment of OVCAR-3 cells with 0.1 mmol/L CA resulted in an enhanced sensitivity to doxorubicin compared with pretreatement with the P-gp inhibitors verapamil or cyclosporin A (Fig. 4B) (Fig. 4C) . We then examined whether CA, like the anthracycline and P-gp substrate daunorubicin, was also sequestered within 786-O cells. Because CA is a fluorescent compound, we used confocal fluorescence microscopy of CA-treated 786-O cells and determined that, like daunorubicin (Fig. 4D) , CA localized within the perinuclear region in vesicles (Fig. 4E) . This observation appears to exclude the known nuclear effect on DNA of anthracyclines as a potential mechanism of cytotoxicity (15) . Because the perinuclear distribution of CA appeared consistent with localization in either the endoplasmic reticulum CA signals were within the Golgi and 54% AE 0.1% of the Golgi compartment showed CA signals (n ¼ 30). Similarly, to confirm the presence of P-gp in the Golgi, we also carried out a colocalization experiment using P-gp immunofluorescence while using GM130 as a Golgi marker in fixed 786-O cells grown on glass cover slips. Here, 46% AE 13% (median AE MAD) of P-gp signals were found within the Golgi and 67% AE 9% of the Golgi compartment showed P-gp signal (n ¼ 30) indicating a significant P-gp presence in the Golgi (Fig. 4F) . The 786-O cells grown on O-and L-shaped fibronectin micropatterns on glass chips (Supplementary Fig. S5 ) to normalize cell position, shape, polarity, and internal organelle positioning also confirmed the presence of P-gp in the Golgi in addition to the cell membrane (16) .
CA induces p115 cleavage
Because CA is sequestered within the Golgi, we next investigated whether effects on Golgi proteins played a role in its proapoptotic activity. Cleavage and import into the nucleus of the C-terminus of the Golgi protein p115 have been shown to promote apoptosis (17) . Western blotting and immunofluorescence examination employing an antibody that recognizes the C-terminus of p115 in CA-treated 786-O cells showed that this fragment was detectable in the nucleus of 786-O cells, whereas none was seen in the nucleus of untreated controls (Fig. 5) .
CA modulates ERGIC-53 activity
To better understand the differential response to CA treatment seen between 786-O and 786-OVHL cells, we asked whether the interaction of Golgi proteins with pVHL afforded 786-OVHL cells protection from the effects of CA. One of the well-studied Golgi proteins known to interact with pVHL is the ER-Golgi intermediate compartment protein ERGIC-53 (also known as LMAN1) that constitutively cycles between the ER, ERGIC, and the cis-Golgi elements (18) . CA treatment produced no significant changes in ERGIC-53 levels in both 786-O and 786-OVHL cells (Fig. 6A) . We, therefore, looked into whether its anterograde and retrograde trafficking was impacted by CA treatment in 786-O cells and whether pVHL afforded protection from effects of CA on its trafficking.
Immunofluorescence confocal experiments revealed that its trafficking was impacted in 786-O cells and showed significantly decreased characteristic accumulation in ERGIC and cis-Golgi elements that is seen in untreated cells (Fig. 6B) . No such disruption was evident in CA-treated 786-OVHL cells. We then looked at export of a well-known ERGIC-53 client protein, A1AT, as a way to assess impact of CA on ERGIC-53 activity (19) . Western blotting revealed that intracellular A1AT levels increased in CA-treated 786-O cells indicating that A1AT was increasingly being retained within treated cells while its levels remained unchanged in treated 786-OVHL cells (Fig. 6A) . We also compared A1AT-secretion from 786-O and 786-OVHL cells after treatment with CA. Conditioned medium from CA or DMSO control-treated 786-O and 786-OVHL cells was examined using an A1AT-specific ELISA. A 3.3-fold increase in secreted A1AT levels was measured in 786-O cells relative to untreated controls (5.01 mg/L/1,000 cells), whereas a 6.2-fold increase was observed in 786-OVHL cells relative to control cells (15.52 mg/L/1,000 cells; Fig. 6C ).
Discussion
The main goal of the work presented above is the demonstration of the utility of a natural product-based screening approach as a viable strategy for exploring newer ways of targeting CCRCC. To date, other than the modulation of HIF-2 activity, there have not been many viable molecular targets proposed for therapeutic discovery in CCRCC. In this regard, we discovered a compound that exploits other vulnerabilities created by genetic and epigenetic alterations that have taken place in CCRCC. The screen employed an unbiased cell-based assay that has led to the identification of CA as a selective inhibitor of CCRCC cell proliferation.
The similarity in the rate of change in XTT reduction of CAtreated paired VHL that the presence of pVHL impacts sensitivity to CA but not the rate of change in cell viability. We found that CA induced apoptosis in VHL À / À cells to a significant extent and that this activity was HIF and p53 independent. At low concentrations, CA induced the activation of caspases-2 and -3 with little or no effect on the activation of caspases-8 or -9. This effect was accompanied by downregulation of the inhibitor of apoptosis protein survivin, a caspase-2 target. Although survivin levels appear to be steady at the 8-hour time point while the level of caspase-2 is increasing in response to CA treatment, this does not necessarily imply that caspase-2 activation does not contribute to survivin downregulation. In fact, stress response to anthracyclines is known to result in the rapid induction of both mRNA and protein of inhibitor of apoptosis proteins including survivin that is followed by a gradual decrease of their expression (20) . We also determined that CA was sequestered within the Golgi in CCRCC cells and that mediation by P-gp, which was also found within the Golgi, was required for its activity. However, whether CA is also sequestered within the Golgi of other P-gp expressing cell lines awaits further investigation. Its localization within the Golgi in CCRCC cells suggests that it might exert its action, at least in part, through effects on Golgi proteins. We, therefore, explored effects of CA on Golgi proteins and whether resistance to CA in VHL þ / þ CCRCC cells was related to interaction of pVHL with Golgi proteins. We found that CA treatment resulted in the detection of the C-terminal fragment of p115 in the nucleus indicating that its apoptotic effects can in part be explained through its effects on p115 (21) . Although CA had no effects on levels of the Golgi protein ERGIC-53, which is one of the few Golgi proteins known to have a direct protein-protein interaction with pVHL, it impacted its distribution pattern between the ER and the Golgi. Our results also indicated that the secretion into the growth medium of A1AT, an ERGIC-53 client, was attenuated while intracellular A1AT levels increased in response to CA treatment. These are consistent with attenuation of function of ERGIC-53 (22) . CA is composed of an aglycone moiety and a monosaccharide residue. Because microsomes from mammalian tissues are known to metabolize anthracyclines to the superoxide anion of the aglycones and their monosaccharide residues through reductive glycosidic cleavage, it can be hypothesized that damage to Golgi proteins by the reactive oxygen species formed from the aglycone may be responsible for the effects of CA on proliferation in CCRCC cells (23) (24) (25) . Alternatively, recognition of the monosaccharide residue in CA as a substrate may lead to attenuation of activity of Golgi proteins. Undoubtedly, however, CA also affects its activity through impact on additional pathways and targets. Demonstration of efficacy in xenograft models is pending preparative scale isolation of CA from the producing microorganism.
In summary, our findings illustrate a potential novel approach for targeting VHL À / À clear cell renal carcinoma.
Our findings also underscore the utility of natural products in yielding compounds that may be used either in therapeutic development or as bioprobes.
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